These effects, combined with the direct neuroprotective effects of Drp1 inhibition [16], as well as the capacity of Mdivi-1 to cross the BBB [5, 12], indicate that Mdivi-1 may have significant potential as a novel MS therapy in the future. Here, DNM1L is linked to myeloid sarcoma.